CARLSBAD, Calif., Dec. 19, 2025 /PRNewswire/ — With the CDC’s Advisory Committee on Immunization Practices (ACIP) recommending post-vaccination antibody testingCARLSBAD, Calif., Dec. 19, 2025 /PRNewswire/ — With the CDC’s Advisory Committee on Immunization Practices (ACIP) recommending post-vaccination antibody testing

Pictor’s Test Poised to Transform Hepatitis B Immunity Testing Amid CDC Guidance Shifts

CARLSBAD, Calif., Dec. 19, 2025 /PRNewswire/ — With the CDC’s Advisory Committee on Immunization Practices (ACIP) recommending post-vaccination antibody testing for hepatitis B, laboratories are facing new demands to assess immunity more effectively. Pictor, a leader in targeted proteomics, today highlighted its ViraScreen-Core™ multiplex antibody assay, an established test already in use by CLIA-certified laboratories, as a ready solution to support this evolving public health guidance. Built for both serum and saliva, the assay offers unmatched flexibility for labs adapting to these changes while addressing broader infectious disease screening needs.

Hepatitis B remains a major global health challenge, yet immunity testing has historically been constrained by cost, operational complexity, and single-analyte approaches. Pictor’s ViraScreen-Core™ assay enables simultaneous detection of antibodies to hepatitis B, HIV-1, HIV-2, and hepatitis C from a single sample, reducing turnaround time, conserving patient samples, and supporting evidence-based clinical decision-making.

“Antibody testing gives laboratories flexibility as public health guidance evolves,” said Dr Jamie Platt, CEO of Pictor. “By offering a multiplex assay that works with both serum and saliva, we aim to help labs move toward evidence-based immunity assessment without adding operational complexity.”

Pictor has completed paired serum and saliva studies demonstrating high concordance, supporting saliva as a reliable testing matrix. This capability may help reduce barriers to testing, particularly in pediatric, community health, and decentralized care settings where blood draws can be challenging.

“Pictor’s ViraScreen-Core™ assay represents a valuable addition to our clinical laboratory,” said Dr Andrew Brown, Chief Commercial Officer at Sirona Dx. “Compatibility with saliva samples expands the environments in which testing can be conducted while the multiplex format supports streamlined, efficient workflows for infectious disease screening.”

Pictor is actively raising capital to support continued commercialization, assay menu expansion, and U.S. deployment of its targeted proteomics platform, building on early laboratory adoption of its technology.

For more information about Pictor’s ViraScreen-Core™ assay, visit www.pictordx.com

About Pictor

Pictor is a leader in flexible, targeted proteomics, delivering next generation multiplex solutions that empower clinical labs, diagnostic manufacturers, and veterinary providers worldwide. Powered by its patented PictArray™ platform, PictImager™, and AI-powered Pictorial™ software, Pictor delivers deeper insights from a single sample, offering faster, more affordable, and scalable results.

From infectious diseases to oncology, Pictor’s innovative technology is advancing both human and animal health, enabling breakthroughs in clinical decision-making. Headquartered in San Diego, Pictor Holdings Inc. is committed to driving innovation through solutions designed for unmatched performance, cost efficiency and productivity.

Discover how Pictor is shaping the future of proteomics testing at www.pictordx.com.

About Sirona Dx

Sirona Dx is technical CRO shaping the next generation of diagnostics to accelerate therapeutic development and advance precision medicine initiatives. Built at the intersection of science and technology, Sirona Dx is driven by innovation because enhanced diagnostics lead to better outcomes. For more information, visit www.sironadx.com.

Legal Disclaimer / Forward-Looking Statements

This press release is not an offer to sell securities or a solicitation of an offer to buy any securities and may not be relied upon in connection with the purchase or sale of any company security. This release may contain forward-looking statements regarding, amongst other things, the company’s expansion plans, product development initiatives, financing objectives, strategic partnership outcomes, and market positioning. Such statements are forward-looking statements and there can be no assurance that the results stated or implied by these forward-looking statements will actually be realized or achieved by the company. Forward-looking statements may be based on management assumptions that could prove to be incorrect. The company’s predictions may not be realized for a variety of reasons as the company’s business is subject to substantial risks and potential events beyond its control that could cause material differences between predicted and actual results.

Media Contact:
Kelly Krueger
415-235-5031
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pictors-test-poised-to-transform-hepatitis-b-immunity-testing-amid-cdc-guidance-shifts-302646920.html

SOURCE Pictor Holdings Inc.

Market Opportunity
B Logo
B Price(B)
$0,20442
$0,20442$0,20442
-%4,12
USD
B (B) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Building a DEXScreener Clone: A Step-by-Step Guide

Building a DEXScreener Clone: A Step-by-Step Guide

DEX Screener is used by crypto traders who need access to on-chain data like trading volumes, liquidity, and token prices. This information allows them to analyze trends, monitor new listings, and make informed investment decisions. In this tutorial, I will build a DEXScreener clone from scratch, covering everything from the initial design to a functional app. We will use Streamlit, a Python framework for building full-stack apps.
Share
Hackernoon2025/09/18 15:05
Which DOGE? Musk's Cryptic Post Explodes Confusion

Which DOGE? Musk's Cryptic Post Explodes Confusion

A viral chart documenting a sharp decline in U.S. federal employment during President Trump's second term has sparked unexpected confusion in cryptocurrency markets
Share
Coinstats2025/12/20 01:13
Google's AP2 protocol has been released. Does encrypted AI still have a chance?

Google's AP2 protocol has been released. Does encrypted AI still have a chance?

Following the MCP and A2A protocols, the AI Agent market has seen another blockbuster arrival: the Agent Payments Protocol (AP2), developed by Google. This will clearly further enhance AI Agents' autonomous multi-tasking capabilities, but the unfortunate reality is that it has little to do with web3AI. Let's take a closer look: What problem does AP2 solve? Simply put, the MCP protocol is like a universal hook, enabling AI agents to connect to various external tools and data sources; A2A is a team collaboration communication protocol that allows multiple AI agents to cooperate with each other to complete complex tasks; AP2 completes the last piece of the puzzle - payment capability. In other words, MCP opens up connectivity, A2A promotes collaboration efficiency, and AP2 achieves value exchange. The arrival of AP2 truly injects "soul" into the autonomous collaboration and task execution of Multi-Agents. Imagine AI Agents connecting Qunar, Meituan, and Didi to complete the booking of flights, hotels, and car rentals, but then getting stuck at the point of "self-payment." What's the point of all that multitasking? So, remember this: AP2 is an extension of MCP+A2A, solving the last mile problem of AI Agent automated execution. What are the technical highlights of AP2? The core innovation of AP2 is the Mandates mechanism, which is divided into real-time authorization mode and delegated authorization mode. Real-time authorization is easy to understand. The AI Agent finds the product and shows it to you. The operation can only be performed after the user signs. Delegated authorization requires the user to set rules in advance, such as only buying the iPhone 17 when the price drops to 5,000. The AI Agent monitors the trigger conditions and executes automatically. The implementation logic is cryptographically signed using Verifiable Credentials (VCs). Users can set complex commission conditions, including price ranges, time limits, and payment method priorities, forming a tamper-proof digital contract. Once signed, the AI Agent executes according to the conditions, with VCs ensuring auditability and security at every step. Of particular note is the "A2A x402" extension, a technical component developed by Google specifically for crypto payments, developed in collaboration with Coinbase and the Ethereum Foundation. This extension enables AI Agents to seamlessly process stablecoins, ETH, and other blockchain assets, supporting native payment scenarios within the Web3 ecosystem. What kind of imagination space can AP2 bring? After analyzing the technical principles, do you think that's it? Yes, in fact, the AP2 is boring when it is disassembled alone. Its real charm lies in connecting and opening up the "MCP+A2A+AP2" technology stack, completely opening up the complete link of AI Agent's autonomous analysis+execution+payment. From now on, AI Agents can open up many application scenarios. For example, AI Agents for stock investment and financial management can help us monitor the market 24/7 and conduct independent transactions. Enterprise procurement AI Agents can automatically replenish and renew without human intervention. AP2's complementary payment capabilities will further expand the penetration of the Agent-to-Agent economy into more scenarios. Google obviously understands that after the technical framework is established, the ecological implementation must be relied upon, so it has brought in more than 60 partners to develop it, almost covering the entire payment and business ecosystem. Interestingly, it also involves major Crypto players such as Ethereum, Coinbase, MetaMask, and Sui. Combined with the current trend of currency and stock integration, the imagination space has been doubled. Is web3 AI really dead? Not entirely. Google's AP2 looks complete, but it only achieves technical compatibility with Crypto payments. It can only be regarded as an extension of the traditional authorization framework and belongs to the category of automated execution. There is a "paradigm" difference between it and the autonomous asset management pursued by pure Crypto native solutions. The Crypto-native solutions under exploration are taking the "decentralized custody + on-chain verification" route, including AI Agent autonomous asset management, AI Agent autonomous transactions (DeFAI), AI Agent digital identity and on-chain reputation system (ERC-8004...), AI Agent on-chain governance DAO framework, AI Agent NPC and digital avatars, and many other interesting and fun directions. Ultimately, once users get used to AI Agent payments in traditional fields, their acceptance of AI Agents autonomously owning digital assets will also increase. And for those scenarios that AP2 cannot reach, such as anonymous transactions, censorship-resistant payments, and decentralized asset management, there will always be a time for crypto-native solutions to show their strength? The two are more likely to be complementary rather than competitive, but to be honest, the key technological advancements behind AI Agents currently all come from web2AI, and web3AI still needs to keep up the good work!
Share
PANews2025/09/18 07:00